GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
GRI Bio (GRI) had its price target lowered by Ascendiant Capital Markets from $1,008.00 to $40.00. They now have a "buy" rating on the stock.
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment [Yahoo! Finance]
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial